4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics, Inc. (FDMT) reports that David Kirn has filed to sell shares of the company’s Class A Common Stock under Rule 144. The notice covers up to 69,076 shares, with an aggregate market value of $1,157,713.76, to be sold through Goldman Sachs & Co. LLC.
The sales are made pursuant to a Rule 10b5-1(c) selling plan dated 01/09/2026. The company discloses that 55,244,211 shares of Class A Common were outstanding. Prior sales by David Kirn in the past three months include, for example, 114,746 shares on 06/22/2026 for $1,200,851.31.
4D Molecular Therapeutics, Inc. executive Scott Bizily, Chief Legal Officer, reported paired option exercises and stock sales in FDMT. On August 13, 2026 and August 17, 2026, Bizily exercised stock options covering 1,635 shares of common stock on each date at an exercise price of $4.14 per share, converting a total of 3,270 stock option rights into common shares. On each of those dates, he then sold 1,635 shares of common stock in open-market or private transactions at per-share prices of $12.00 and $12.20, respectively. These sales were made pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026. The exercised options relate to an award that vests monthly, with 1/48th of the underlying shares vesting each month starting on March 6, 2025 until fully vested on the fourth anniversary, while Bizily remains a service provider.
4D Molecular Therapeutics (symbol FDMT) reports a planned sale of 6,540 shares of common stock on 08/17/2026 through Morgan Stanley Smith Barney LLC, following an Exercise of Stock Options for cash. The shares are listed on NASDAQ. The filing also lists prior programmed sales under a 10b5-1 trading plan for Scott Bizily over the past three months.
A stockholder of FDMT, working through Morgan Stanley Smith Barney LLC’s Executive Financial Services, filed to sell 1,635 common shares on NASDAQ on 08/13/2026, with the shares to be issued via an exercise of stock options for cash. The filing also lists prior Rule 10b5-1 plan sales by Scott Bizily over the past three months, including 6,566 shares for $91,924.00 on 06/30/2026 and 9,810 shares for $117,720.00 on 06/23/2026.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company developing AAV genetic medicines and remains pre-commercial with no product sales. For the three months ended June 30, 2026, collaboration and license revenue was $3.8 million, and for the six months it totaled $6.8 million, driven largely by its regional partnership with Otsuka for 4D-150 and its Cystic Fibrosis Foundation agreement.
The company recorded a net loss of $72.9 million in the quarter and $141.7 million year-to-date, compared with $54.7 million and $102.6 million in the prior-year periods, and its accumulated deficit reached $858.0 million. Research and development expenses for the first half of 2026 were $133.3 million, reflecting intensive clinical and preclinical activity.
As of June 30, 2026, cash, cash equivalents and marketable securities had a combined fair value of about $430.6 million, and total assets were $492.6 million. Management states these resources are sufficient to fund planned operations for at least one year. During the period, 4D Molecular Therapeutics also put in place a $200.0 million term loan facility with Hercules Capital and drew an initial $20.0 million, adding modest long-term debt to its balance sheet.
4D Molecular Therapeutics reported Q2 2026 results highlighted by late-stage clinical progress and a strengthened balance sheet. Cash, cash equivalents and marketable securities were $430.6 million as of June 30, 2026, which, together with expected Otsuka collaboration payments, is estimated to fund operations into the second half of 2028. The company also entered a strategic credit facility with Hercules Capital for up to $200 million, drawing $20 million at closing.
Collaboration and license revenue was $3.8 million in Q2 2026, while research and development expenses rose to $68.3 million and general and administrative expenses to $12.5 million. Net loss was $72.9 million, or $1.04 per share. Clinically, enrollment was completed in both 4FRONT-1 and 4FRONT-2 Phase 3 trials of 4D-150 for wet AMD, with topline data expected in 2027, and a Phase 3 DME trial is planned to start in Q3 2026. Two-year PRISM Phase 2b data showed sustained visual outcomes and a 78–87% reduction in treatment burden versus projected aflibercept dosing, with a favorable safety profile.
4D Molecular Therapeutics, Inc. director and officer David Kirn sold 26,842 shares of common stock on August 4, 2026 at a weighted average price of $10.2301 per share. The sale was executed in multiple trades between $10.07 and $10.42 pursuant to a 10b5-1 trading plan adopted January 9, 2026. After this transaction, he directly owns 844,895 common shares.
The issuer of FDMT Class A Common Stock has a planned sale of up to 26,842 shares, to be executed through Goldman Sachs & Co. LLC on the NASD on or about August 4, 2026, with an aggregate market value of $275,398.92. The shares were acquired from the issuer in a private transaction on December 15, 2020.
Over the prior three months, shareholder David Kirn reported multiple sales of Class A Common Stock, including 114,746 shares for $1,200,851.31 on June 22, 2026, 42,608 shares for $548,177.48 on July 9, 2026, and several smaller transactions on June 1, July 10, and August 3, 2026.
4D Molecular Therapeutics, Inc. President and Chief Executive Officer David Kirn sold 12,415 shares of common stock on August 3, 2026 at a weighted average price of $10.0461 per share, pursuant to a 10b5-1 trading plan adopted January 9, 2026, and now directly holds 871,737 shares.
FDMT shareholder David Kirn has filed a notice of proposed sale of 12,415 shares of Class A Common Stock, to be sold through Goldman Sachs & Co. LLC on or after August 3, 2026 on the NASD market. The proposed sale has an aggregate market value of $125,267.35. The issuer reports 52,276,254 Class A Common shares outstanding.
The shares to be sold were acquired from the issuer in a private transaction dated December 15, 2020. Over the past three months, David Kirn has sold Class A Common Stock in several transactions, including 1,922 shares for $19,257.86 on June 1, 2026, 114,746 shares for $1,200,851.31 on June 22, 2026, 42,608 shares for $548,177.48 on July 9, 2026, and 15,725 shares for $189,233.08 on July 10, 2026.